组织蛋白酶K抑制剂 Odanacatib 研究进展

摘要：骨质疏松症患病率近年来明显增加，社会危害巨大。破骨细胞功能活化是骨质疏松发生的重要原因。组织蛋白酶是破骨细胞表达的一类酶，参与有机质的降解，与骨质疏松的发生密切相关。其中组织蛋白酶K是最重要的一种酶，组织蛋白酶K抑制剂Odanacatib(ODN)可以通过抑制其对有机质的降解治疗骨质疏松。在目前进行的一些研究中发现，应用ODN可以增加皮质厚度和小梁骨的骨矿含量，因此增加骨密度和骨的负荷强度。本文就ODN的药理特性，动物试验及临床研究的进展进行综述。

Progress in Cathepsin K Inhibitor Odanacatib

[Abstract] The prevalence of osteoporosis has increased during recent years. The activation in the function of osteo?clast is the main reason of osteoporosis. Cathepsin is expressed by osteoclast and involved in the degradation of collagen of bone, and causes osteoporosis. Cathepsin K is a kind of most important enzyme in the family of cathepsin. Odanacatib（ODN）is the inhibitor of cathepsin K, and it may be used to anti-osteoporosis thought inhibiting the degradation of bone collagen. It was found that the cortical thickness and bone minerals of cancellous increased after taking ODN in the studies, and then the density and the strength of bone increased. This study reviewed the pharmacological profile of ODN and the progresses of animal study and clinical trials about ODN.